<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: N-[[4-[[[(2-ethylphenyl)amino]<z:chebi fb="1" ids="23019">carbonyl</z:chebi>]amino]<z:chebi fb="1" ids="30396">phenyl</z:chebi>]<z:chebi fb="9" ids="46887">acetyl</z:chebi>]-N(epsilon)-6-[(2E)-1-oxo-3-(3-<z:chebi fb="0" ids="51635">pyridinyl</z:chebi>-2-propenyl)]-l-<z:chebi fb="0" ids="32568">lysyl</z:chebi>-l-2-aminohexanedioyl-(1-amino-1-<z:chebi fb="0" ids="29005">cyclohexane</z:chebi>)<z:chebi fb="0" ids="23004,37622">carboxamide</z:chebi> (LLP2A) is a high-affinity, high-specificity peptidomimetic ligand (inhibitory concentration of 50% = 2 pM) that binds the activated alpha4beta1 integrin found on a variety of malignant lymphoid cell lines </plain></SENT>
<SENT sid="1" pm="."><plain>To better determine whether this ligand holds promise for imaging and therapy in lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, 6 LLP2A derivatives, as LLP2A-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (LLP2A-DOTA) and LLP2A-DOTA-<z:chebi fb="1" ids="46793">polyethylene glycol</z:chebi> (LLP2A-DOTA-<z:chebi fb="77" ids="46793">PEG</z:chebi>), were designed, synthesized, and radiolabeled with (111)In </plain></SENT>
<SENT sid="2" pm="."><plain>Comparative pharmacokinetic studies in mice with Raji B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> xenografts were then complemented by small-animal PET of the lead molecular LLP2A format using (64)Cu-LLP2A-11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]<z:chebi fb="0" ids="45296">hexadecane</z:chebi> ((64)Cu-LLP2A-CB-TE2A) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: LLP2A-DOTA and LLP2A-CB-TE2A were prepared using solid-phase synthesis; LLP2A-DOTA-<z:chebi fb="77" ids="46793">PEG</z:chebi>(2,000), LLP2A-DOTA-<z:chebi fb="77" ids="46793">PEG</z:chebi>(5,000), LLP2A-DOTA-<z:chebi fb="77" ids="46793">PEG</z:chebi>(10,000), (LLP2A-DOTA)(2)<z:chebi fb="77" ids="46793">PEG</z:chebi>(10,000), and (LLP2A-DOTA)(4)<z:chebi fb="77" ids="46793">PEG</z:chebi>(10,000) were prepared by PEGylation </plain></SENT>
<SENT sid="4" pm="."><plain>(111)In radiolabeling of DOTA and (64)Cu radiolabeling of CB-TE2A conjugates yielded 370-1,850 and 3,700-7,400 kBq/microg (10-50 and 100-200 microCi/microg), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The pharmacokinetics of the six (111)In radioconjugates were studied in vivo using biodistribution data (4 and 24 h) and whole-body autoradiography (24 h) in mice with Raji <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts </plain></SENT>
<SENT sid="6" pm="."><plain>(64)Cu-LLP2A-CB-TE2A was imaged (4 and 24 h) on a small-animal PET scanner in the same mouse model </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The highest <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake in pharmacokinetic studies was obtained with LLP2A-DOTA and (LLP2A-DOTA)(4)-<z:chebi fb="77" ids="46793">PEG</z:chebi>(10,000) </plain></SENT>
<SENT sid="8" pm="."><plain>For (111)In-LLP2A-DOTA (1 nM) at 4 and 24 h after injection, ratios of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> to blood and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> to nontumor (<z:mpath ids='MPATH_458'>normal</z:mpath>) organ (T/NT) were 8 to 35:1 for <z:hpo ids='HP_0000001'>all</z:hpo> organs or tissue except the spleen, marrow, and kidney, which were between 2:1 and 1:1 </plain></SENT>
<SENT sid="9" pm="."><plain>Tetravalent (LLP2A-DOTA)(4)-<z:chebi fb="77" ids="46793">PEG</z:chebi>(10,000) (1.1 nM) had <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake similar to the univalent LLP2A-DOTA but higher liver, marrow, and kidney uptake </plain></SENT>
<SENT sid="10" pm="."><plain>The excellent T/NT of LLP2A was also demonstrated by small-animal PET with (64)Cu-LLP2A-CB-TE2A at both 4 and 24 h after injection; obvious spleen targeting was apparent, but little kidney or liver activity was observed </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Of the conjugates investigated, the univalent, non-PEGylated ligand (111)In-LLP2A-DOTA exhibited the best T/NT ratios and showed the greatest potential for imaging of alpha4beta1 in human <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Furthermore, this univalent non-PEGylated LLP2A format, as (64)Cu-LLP2A-CB-TE2A, demonstrated excellent <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> targeting by small-animal PET and warrants further investigation as an agent for the study of alpha4beta1 expression in human lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>